— Know what they know.
Not Investment Advice

XCUR NASDAQ

Exicure, Inc.
1W: -5.7% 1M: -10.8% 3M: -42.2% YTD: -79.4% 1Y: -72.0% 3Y: -67.6% 5Y: -99.4%
$1.15
-0.03 (-2.54%)
 
Weekly Expected Move ±10.5%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 26 · $7.3M mcap · 2M float · 22.46% daily turnover · Short 44% of daily vol

Supply Chain Overview

13 relationships
13
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-08-02
Earliest Filing
2025-05-06
Latest Filing
investor: 8 acquirer: 2 partner: 2 target: 1

Counterparties (Filed by XCUR)

13 relationships

Companies named in XCUR's SEC 8-K filings as business counterparties.

Counterparty Ticker Relationship Summary Filing Date SEC
KC Creation Co., Ltd. — investor Exicure, Inc. purchased non-guaranteed private placement convertible bonds from KC Creation Co., Ltd. 2025-05-06 View
Shin Chang Partners — investor Purchased 145,454 shares of common stock for $5.50 per share 2025-02-21 View
RMS0718 Co., Ltd. — investor Purchased 145,454 shares of common stock for $5.50 per share 2025-02-21 View
GPCR Therapeutics Inc — acquirer Acquired GPCR USA and entered into a License and Collaboration Agreement 2025-01-22 View
GPCR USA — target Target company acquired by Exicure Inc. 2025-01-22 View
HiTron Systems Inc. — investor Agreed to purchase 3,333,000 shares of common stock for approximately $10 million in two separate transactions. 2024-11-14 View
Flashpoint Therapeutics, Inc. — acquirer Purchased Exicure's spherical nucleic acid-related technology, research and development programs, and clinical assets fo 2024-09-30 View
DGP Co., Ltd. — investor Debt-for-equity exchange for $700,000 promissory note resulting in issuance of 237,233 shares 2024-09-13 View
Cyworld Z Co., Ltd. — investor Exicure, Inc. purchased non-guaranteed private placement convertible bonds from Cyworld Z Co., Ltd. 2023-05-18 View
Cyworld Z Co., Ltd. — investor Exicure, Inc. purchased non-guaranteed private placement convertible bonds from Cyworld Z Co., Ltd. 2023-05-09 View
CBI USA, Inc. — investor Acquired 3,400,000 shares of common stock in a private placement for $5.4 million and holds registration rights. 2022-09-27 View
IPSEN BIOPHARM LIMITED — partner Entered into a Collaboration, Option and License Agreement for SNA-based therapeutics targeting Huntington's Disease and 2021-08-02 View
Northwestern University — partner Received a portion of payments pursuant to existing license agreements and a side letter clarifying sublicenses. 2021-08-02 View
Recent 8-K Filings (20)
Filing Date Description Type SEC
2026-09-16 Delisting Notice View
2026-06-30 Officer/Director Change View
2026-06-01 Regulation FD View
2026-04-10 Officer/Director Change View
2026-04-02 Other Events; Exhibits View
2026-03-27 Officer/Director Change View
2026-03-25 Earnings Release; Exhibits View
2026-02-17 Departure/Election of Directors; Appointment of Officers View
2026-02-10 Departure/Election of Directors; Appointment of Officers View
2026-01-22 Other Events; Financial Statements and Exhibits View
2025-11-17 Other Events; Financial Statements and Exhibits View
2025-11-10 Submission of Matters to a Vote of Security Holders View
2025-11-07 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2025-09-09 Departure/Election of Directors; Appointment of Officers View
2025-08-08 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2025-08-04 Other Events View
2025-06-27 Financial Statements and Exhibits View
2025-06-10 Departure/Election of Directors; Appointment of Officers View
2025-05-28 Notice of Delisting or Transfer; Other Events View
2025-05-06 Entry into Material Definitive Agreement Agreement View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms